Physician profile
Robert Grana
NPI 1528232279
$902.72
in general payments reported to CMS, 2019-2025
10 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.38 · 2021: $113 · 2022: $44.46 · 2023: $219 · 2024: $408 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $162.19 | 2023-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $154.49 | 2024 | Optimizer |
| Medtronic, INC. | $150.00 | 2023 | Cobalt Dr Mri Surescan |
| Pfizer INC. | $126.88 | 2024-2025 | |
| Novo Nordisk INC | $100.16 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $86.66 | 2021-2024 | |
| Abbott Laboratories | $47.57 | 2021 | |
| Boston Scientific Corporation | $45.00 | 2021 | |
| Amgen INC. | $18.39 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Grana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.